AUK
From the latest quarterly:
•Cash receipts of A$4.9m – up 1461% vs previous corresponding period (PCP) (A$312,000Q3 FY23).
• Annual revenues (year to date) now totaling A$20.9m – surpassing FY23 total sales(A$2.6m) by 674% with one quarter remaining.
- The Company remains well funded with a cash balance of A$2.3m – up 39% from the previous quarter (A$1.6m)
and
a $300m deal with the Chinese announced yesterday
something got to give...
- Forums
- ASX - Day Trading
- Morning Trading July 23
Morning Trading July 23, page-149
Featured News
Featured News
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online